Japanese guideline for the treatment of idiopathic pulmonary fibrosis

Sakae Homma,Masashi Bando,Arata Azuma,Susumu Sakamoto,Keishi Sugino,Yoshiki Ishii,Shinyu Izumi,Naohiko Inase,Yoshikazu Inoue,Masahito Ebina,Takashi Ogura,Kazuma Kishi,Tomoo Kishaba,Takashi Kido,Akihiko Gemma,Yoshihito Goto,Shinichi Sasaki,Takeshi Johkoh,Takafumi Suda,Kazuhisa Takahashi,Hiroki Takahashi,Yoshio Taguchi,Hiroshi Date,Hiroyuki Taniguchi,Takeo Nakayama,Yasuhiko Nishioka,Yoshinori Hasegawa,Noboru Hattori,Junya Fukuoka,Atsushi Miyamoto,Hiroshi Mukae,Akihito Yokoyama,Ichiro Yoshino,Kentaro Watanabe,Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society

DOI: https://doi.org/10.1016/j.resinv.2018.03.003

Abstract:Idiopathic pulmonary fibrosis (IPF) is a disease of unknown etiology which accounts for a large proportion of cases of idiopathic interstitial pneumonia. It has a very poor prognosis with a 5-year survival rate of 30% or below, and so far there has been no guideline in Japan offering an established effective therapy based on evidence. In addition to the establishment of basic therapies, there is also an urgent need to establish therapies to deal with complications, as death occurs in many cases due to acute exacerbation or comorbid lung cancer. It was therefore decided to formulate a guideline in order to promote evidence-based clinical practice, to further improve the quality of medical treatment in the clinical setting, and to allow the benefits to be enjoyed by the public.